Abstract
A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma. While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment. We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Immunophenotyping
-
Liver / diagnostic imaging
-
Liver / drug effects
-
Liver / pathology
-
Lymph Nodes / pathology
-
Lymphoma, B-Cell / immunology*
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell / therapy*
-
Male
-
Neoplasm Recurrence, Local
-
Remission Induction
-
Rituximab
-
Spleen / diagnostic imaging
-
Spleen / drug effects
-
Spleen / pathology
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / pathology
-
Tomography, X-Ray Computed
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab